Neurofilament light chain may be a potential biomarker for predicting progression of Alzheimer's disease
Serum NfL predicts disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer’s disease, as per a study reported in Nature Medicine. Serum neurofilament light chain (NfL) levels correlated with NfL levels in the cerebrospinal fluid (CSF) and were elevated at pre-symptomatic stages of familial Alzheimers disease There were noticeable changes in blood up to 16 years before the calculated onset of dementia symptoms.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies